TheStockWizards.net: TheStockWizards.net: News and Technical Analysis Updates for February 9th 2010 OWVI, CBAI, GETA, SHMN, IMSC

Boca Raton FL, www.TheStockWizards.net a Premiere Financial Portal & Investor Relations Firm that brings a wealth of trading resources to Small Cap Investors, has compiled a list of stocks on the OTCBB, and Pink Sheet Markets that have positive technical indicators and may provide continued trading opportunities for investors. Recent stocks of interest include OWVI, CBAI, GETA, SHMN, IMSC

*** One World Ventures, Inc. (PINKSHEETS: OWVI | Quote | Chart | News | PowerRating) LAS VEGAS, NV, Feb 08, 2010 One World Ventures, Inc. announced it will release financial results for its fiscal year 2009 after Market close on February 11, 2010.

Technical outlook: OWVI broke above the critical resistance level of .004 and hit a intraday high of .0047, but came back down and close below the much anticipated breakout level of .004. This level will be of major significance in the future for the stock making higher highs. We feel the stock has good support in the area of .0029-.0030 area.

One World Ventures, Inc. invests in technologies, communities, and systems that facilitate trade, finance, communication, and travel across international boundaries, cultures, and languages. The company, through its subsidiaries, provides online marketing services for individuals and businesses to buy and sell their products and services; and auctions various product and services, including collectibles, appliances, computers, furniture, clothing, toys, and vehicles. It also offers debit card systems and technologies that enable its customers to access over various automated teller machines worldwide and online purchasing. In addition, the company provides consulting services specializing in product development and management. One World Ventures, Inc. is based in Las Vegas, NV.

*** LAS VEGAS, Feb 08, 2010 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, said today that it has finalized an agreement to process and store cord blood specimens for BioCells, Inc., headquartered in Argentina, and its affiliates in Peru, Colombia, Bolivia, Panama and Puerto Rico.

Technical outlook: CBAI was very oversold and bounced off that important support level of .007. We feel that this is a major support level and traders and investors should take notice. We see a possible bounce back to the .01 area Cord Blood America, Inc., through its subsidiaries, provides private cord blood stem cell preservation services to families. The company also focuses on collecting, processing and preserving peripheral blood and adipose tissue stem cells allowing individuals to privately preserve their stem cells for potential future use in stem cell therapy. In addition it creates direct response television and radio advertising campaigns, including media placement and commercial production. Subsidiaries The company's subsidiaries include Cord Partners, CorCell Co. Inc., CorCell Ltd., (Cord), CBA Professional Services, Inc. D/B/A BodyCells, Inc. (BodyCells), CBA Properties, Inc. (Properties), and Career Channel Inc, D/B/A Rainmakers International (Rain). CORD Services Provided By Cord Cord?s customers are typically expectant parents who choose to collect and store umbilical cord blood at the birth of their child for potential use in a stem cell transplant at a later date for that child or for another family member. Through partnering with Progenitor Cell Therapy, LLC (PCT), Cord is able to provide services to collect, test, process and preserve umbilical cord blood. Collection: The company provides a kit that contains all of the materials necessary for collecting the newborn's umbilical cord blood at birth and packaging the unit for transportation

*** BERKELEY HEIGHTS, N.J., Feb 08, 2010 Genta Incorporated (OTCBB: GETA) announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta's experience in melanoma clinical research.

Technical outlook: GETA is still trading in a tight range between .10 and .12. The stock did break its 50 day moving average which is at .10. Short term resistance is at .19 while .10 is major support at this time.

Genta Incorporated, a biopharmaceutical company, engages in the identification, research, development, and commercialization of pharmaceutical drugs for the treatment of cancer and related diseases. Research and Development Programs The company's research portfolio comprises two programs: DNA/RNA Medicines and Small Molecules. DNA/RNA Medicines the DNA/RNA Medicines program includes drugs that are based on using modifications of either DNA or RNA as drugs that would be used to treat disease. These technologies include antisense, decoys, and small interfering or micro RNAs

*** BUENA PARK, CA, Feb 08, 2010 SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, announced today that is has signed a marketing agreement adding 75 branded generic pharmaceutical products for distribution across India. The new product offerings take the Company's total to 135.

Technical outlook: SHMN had a nice breakout two days ago over the .10 area in conjunction with the 50 day moving average. The stock has been on a two-day run with major resistance at .20-.21 area SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. . Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia.

*** WILMINGTON, Mass., Feb 08, 2010 Implant Sciences Corporation (OTCBB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, has been issued a coveted "Designation" for its Quantum Sniffer(TM) technology under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act) from the U.S. Department of Homeland Security. The designation applies to the company's QS-H100 and QS-H150 Portable Explosives Detectors.

Technical outlook: IMSC has been in a trading range between .30 and .40. If the stock can break above .40 you should see another round of major buying. The stock is currently above its 10 day moving average which is .35.

Implant Sciences Corporation engages in the development, manufacture, and sale of sensors and systems for the security, safety, and defense (SS&D) industries. The company offers its products in the United States and China. The company has developed proprietary technologies used in explosives trace detection (ETD) applications; and markets and sells handheld and bench-top ETD systems that use its proprietary ETD technologies. Its products are marketed and sold to various locations domestically and internationally. These systems are used by private companies and government agencies to screen baggage, cargo, vehicles, other objects, and people for the detection of trace amounts of explosives. Products The Company offers various explosives detection systems designed for use in aviation and transportation security, high threat facilities and infrastructure, military installations, customs and border protection, and mail and cargo screening. The systems use its proprietary Quantum Sniffer technologies, including photon-based, non-radioactive ion source in combination with ion mobility spectrometry, a detection tool sensitive to the speeds with which ions of various substances move through the air (IMS) to electronically detect minute quantities of explosives vapor and particles.

Some of the features of www.thestockwizards.net include

** Award-Winning trading articles that will help new and old investors and traders enhance their trading skills. See our new article under our section called Traders Corner.

http://thestockwizards.net/traders/dont-invest-or-trade-another-penny-stock-until-you-read-this/

** Video Charts: We educate traders and investors with visual presentations on how to use technical analysis when making decisions on entering and exiting stock positions.

Sign-up for our free e-mail service as we scour the market for stocks that have the potential to move big. See our website for past picks.

Please visit our website for disclosures and disclaimers and any conflicts of interest that there may be. http://thestockwizards.net/disclaimer

CONTACT: TheStockWizards.net Tel: +1 954 643 7400 e-mail: info@thestockwizards.net WWW: http://thestockwizards.net

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (OWVI) OWVI. (OWVI) has Short Term PowerRatings at TradingMarkets. Details on (OWVI) Short Term PowerRatings is available at This Link.